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Objectives: To assess the relative efficacy of canagliflozin, a sodium glucose co-
transporter 2 inhibitor (SGLT2) as add-on to insulin +/- oral antihyperglycaemic 
drugs for the treatment of T2DM compared to dipeptidyl peptidase-4 inhibitors 
(DPP-4s), glucagon-like peptide-1 receptor agonists (GLP-1s), sulphonylureas, piogl-
itazone, and other SGLT2 inhibitors, using Bayesian NMA methods. MethOds: 
A systematic literature review was conducted according to NICE guidelines and 
available data on HbA1c, weight and systolic blood pressure (SBP) were extracted. 
Networks were based on treatment- and dose-specific nodes, except for sulphonylu-
reas where doses were combined. Selection of fixed versus random effects was based 
on the deviance information criterion. Results were interpreted based on absolute 
differences and Bayesian probabilities for treatments to perform better than others 
(P), where P≤ 30% indicated a smaller effect and P≥ 70% a larger effect. Results: 
Eighteen trials reported results at 26 +/- 4 weeks. HbA1c reductions were highest 
for liraglutide 1.8mg, pioglitazone 45mg and glibenclamide. Canagliflozin 300mg 
had greater HbA1c reductions than all remaining comparators, except for exenatide 
where the reduction was similar. Canagliflozin 100mg had a greater reduction than 
dapagliflozin 5mg, vildagliptin, saxagliptin and lixisenatide and a similar reduction 
versus DPP-4s, glimepiride, lixisenatide, pioglitazone 30mg, metformin and dapa-
gliflozin 10mg. Both dosages of canagliflozin were associated with greater weight 
loss than DPP-4s, glibenclamide, pioglitazone 30mg and dapagliflozin (Δ = –2.13 to 
–3.45kg; Δ = –7.61 to –8.25kg; Δ = –3.34 to –3.95kg; Δ = –0.44 to –1.73kg, respectively). 
Weight reductions were highest for liraglutide 1.8mg and exenatide 10μ g. Both dos-
ages of canagliflozin had higher SBP reductions than dapagliflozin and saxagliptin; 
at least similar reductions were estimated versus exenatide 10μ g. cOnclusiOns: 
These results suggest that canagliflozin is a valuable treatment option as add-on 
to insulin therapy, as it provides not only similar or better glucose lowering than 
many other options, but also weight loss.
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Objectives: Improving glycaemic control is the primary goal of T2DM manage-
ment and can help to reduce the risk of micro- and macrovascular complications. 
Guidelines from the European Association for the Study of Diabetes (EASD) and 
the National Institute for Health and Care Excellence (NICE) recommend lower-
ing HbA1c to levels < 7.0% and < 7.5%, respectively. Canagliflozin, an agent that 
inhibits sodium glucose co-transporter 2, has been shown to reduce HbA1c, body 
weight, and blood pressure in a broad range of patients with T2DM. The objective 
of this study was to evaluate the proportions of T2DM patients achieving glycaemic 
targets with canagliflozin 100mg (CANA100) and canagliflozin 300mg (CANA300) 
versus placebo in triple therapy as add-on to metformin plus sulphonylurea 
(MET+SU). MethOds: Data were used from a 52-week Phase 3 study evaluating 
CANA100 and CANA300 versus placebo in T2DM patients on background MET+SU 
(N= 457; mean HbA1c, 8.1%). The proportions of patients with baseline HbA1c ≥ 7.0% 
or ≥ 7.5% who achieved HbA1c < 7.0% or < 7.5%, respectively, were assessed at weeks 
26 and 52. Patients with missing efficacy data were considered as non-responders. 
Odds ratios (ORs; [95% confidence interval]) by treatment were calculated using 
logistic regression. Results: Among patients with baseline HbA1c ≥ 7.0% (n= 425), a 
higher proportion achieved HbA1c < 7.0% with CANA100 (29.1%; OR= 2.65 [1.47;4.95]) 
and CANA300 (40.1%; OR= 4.34 [2.45;7.98]) versus placebo (13.4%; reference) at week 
52. Similarly, a higher proportion of patients with baseline HbA1c ≥ 7.5% (n= 330) 
achieved HbA1c < 7.5% with CANA100 (45.5%; OR= 4.13 [2.24;7.91]) and CANA300 
(54.1%; OR= 5.82 [3.15;11.15]) versus placebo (16.8%; reference) at week 52. Absolute 
response rates were higher at 26 weeks, but relative treatment effects were consist-
ent between 26 and 52 weeks. cOnclusiOns: Patients with T2DM treated with 
canagliflozin 100 and 300mg as add-on to MET+SU are more likely to achieve HbA1c 
targets of < 7.0% and < 7.5% compared to MET+SU only.
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Objectives: For people with Type 2 Diabetes Mellitus (T2DM) insufficiently con-
trolled with oral antidiabetic drugs (OADs), GLP-1 analogues proved to offer glycae-
mic control while mitigating the weight gain common with insulin. However, limited 
head-to-head evidence exists comparing daily GLP-1 analogues in this population. 
The aim of this study was to evaluate the relative efficacy and safety of liraglutide 
relative to other daily GLP-1 agonists for the treatment of people with T2DM not 
previously treated with insulin. MethOds: Following a systematic literature review, 
randomized controlled trials evaluating the following interventions in adults with 
T2DM were selected: liraglutide (1.2mg and 1.8mg), exenatide (5mcg and 10mcg 
BID), and lixisenatide (20mcg). Based on the available data we conducted network 
meta-analysis (NMA) for the following outcomes: Change from baseline HbA1c, 
proportion of patients meeting HbA1c target level, fasting plasma glucose (FPG), 
post-prandial glucose (PPG), systolic blood pressure (SBP), and weight, as well as 
rates of hypoglycemic events (severe and mild). Results: Liraglutide was found to 
conducted. Randomised controlled trials (RCTs) were of 24 weeks (± 6 weeks) treat-
ment duration. Bayesian fixed-effect (FE) and random-effects (RE) models were 
used to estimate the relative efficacy and tolerability, and 95% credible intervals 
(CrIs). Results: Fourteen RCTs were included. The RE model was selected a prio-
riover the FE model. The FE model did not provide a better fit to the data, based 
on the deviance information criterion. EQW was statistically significantly better 
than placebo (mean; 95% CrI) (-1.09%; -1.62% to -0.53%) in reducing HbA1c. EQW 
obtained a statistically significant reduction in HbA1c relative to lixisenatide 20ug 
QD. Favourable point estimates that did not reach statistical significance were 
observed for EQW vs. albiglutide 30mg QW, exenatide 5ug and 10ug twice daily 
(BID), and liraglutide 1.2mg and 1.8mg once daily (QD). A model adjusting for base-
line HbA1c did not provide a better fit to the data than the unadjusted model. 
EQW was associated with a lower risk of nausea compared to all GLP-1 RAs, except 
exenatide 5ug BID (none of these differences were statistically significant). Risk 
of discontinuation due to adverse events was lower for EQW than for dulaglutide 
1.5mg QW, and liraglutide 1.2mg and 1.8mg QD, and higher for EQW than for lixi-
senatide 20ug QD and exenatide 5ug and 10ug BID (none of these differences were 
statistically significant). cOnclusiOns: Evidence suggests that EQW is an effective, 
well-tolerated therapeutic option for the treatment of T2DM in adults inadequately 
controlled on MET alone.
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Objectives: The growing prevalence of T2DM in Europe poses a significant economic 
and healthcare burden, mainly due to diabetes-related complications. Maintaining 
HbA1c below 7% has been shown to reduce the risk of complications in the longer 
term. In the absence of direct evidence comparing sodium glucose co-transporter 
2 (SGLT2) inhibitors, indirect comparisons are needed to inform clinical and policy 
decisions. This analysis assessed the proportion of patients reaching the defined 
HbA1c goal of less than 7% with canagliflozin versus dapagliflozin and empagliflo-
zin added to MET+SU. MethOds: A systematic literature review identified 14 ran-
domised controlled trials, which were used to perform a Bayesian NMA to estimate 
the relative efficacy of canagliflozin added to MET+SU at 26±4 weeks. Relative efficacy 
was evaluated based on odds ratios (ORs) of the proportions of patients reaching 
the HbA1c target and Bayesian pairwise probabilities (P). Interpretation of results 
was based on ORs and P, where P≤ 30% indicated a smaller effect and P≥ 70% a larger 
effect. Results: Canagliflozin 100 mg had similar odds of reaching HbA1c< 7% 
compared to dapagliflozin 10 mg and empagliflozin 25 mg (ORs of 1.12 [P= 60%] and 
0.94 [P= 44%], respectively), and higher odds versus empagliflozin 10 mg (OR of 1.26 
[P= 73%]). Patients treated with canagliflozin 300 mg had higher odds of reaching 
HbA1c< 7% versus dapagliflozin 10 mg and empagliflozin 25 and 10 mg (ORs of 2.03 
[P= 94%], 1.71 [P= 93%], and 2.29 [P= 99%], respectively). cOnclusiOns: This NMA of 
add-on therapies to MET+SU suggests that the odds of achieving HbA1c< 7% at 26 
weeks were at least similar for canagliflozin 100 mg and greater for canagliflozin 300 
mg versus dapagliflozin and empagliflozin.
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Objectives: To assess the relative efficacy of canagliflozin, a sodium glucose 
co-transporter 2 (SGLT2) inhibitor, as add-on to metformin, versus newer anti-
hyperglycaemic agents (AHAs) that were not studied in phase 3 trials, namely 
glucagon-like peptide-1 receptor agonists and other SGLT2 inhibitors (i.e., dapa-
gliflozin and empagliflozin). Data from trials 102 to 104 weeks in length were 
included to compare the longer-term efficacy. MethOds: Bayesian NMAs of 
HbA1c, weight and systolic blood pressure (SBP) change were conducted. Networks 
had treatment- and dose-specific nodes where feasible. As two different meth-
ods to account for missing data were used in the publications (last observation 
carried forward [LOCF] and mixed model repeated measures [MMRM]), two sepa-
rate networks were constructed for each outcome. Interpretation of results was 
based on absolute differences and Bayesian probabilities for treatments to perform 
better than others (P), where P≤ 30% and P≥ 70% indicated a smaller and larger 
effect, respectively. Results: The systematic review identified 11 studies. Seven 
and five studies were included in LOCF and MMRM networks, respectively. In the 
LOCF analysis, canagliflozin 300mg ranked first with greater HbA1c reductions 
than liraglutide 1.2mg/1.8mg and empagliflozin 25mg (D= –0.11%, –0.09%, –0.08%); 
canagliflozin 100mg had similar HbA1c reductions. Both canagliflozin doses had 
higher weight reductions than liraglutide 1.2mg/1.8mg and similar reductions 
versus empagliflozin 25mg. Both canagliflozin doses had greater SBP-lowering 
than liraglutide 1.2mg/1.8mg (D= –1.11 to –2.68mmHg) and a lower effect versus 
empagliflozin 25mg (D= 0.81 to 1.87mmHg). In the MMRM network, canagliflozin 
300 and 100mg had greater and similar HbA1c reductions, respectively, versus 
dapagliflozin. Weight loss was marginally higher for dapagliflozin (D= 0.42 to 
0.59kg). Both canagliflozin doses conferred at least similar SBP-lowering versus 
dapagliflozin. cOnclusiOns: These NMAs suggest that over 2 years, canagliflozin 
offers the opportunity for improved glycaemic control compared with other AHAs, 
with the added benefits of weight loss and BP reduction.
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sensus, the assessment of a third investigator was requested. Results: Bariatric 
surgery showed to be effective and safe in reducing glycated hemoglobin levels, 
fasting blood glucose levels as well as the augmenting the chances of remission 
of type II diabetes in obese patients. cOnclusiOns: However, the variability in 
the magnitude of the results indicated the need for new data from the 18 ongoing 
clinical trials. In other words, the technology “bariatric surgery” is efficacious as a 
whole, but there is a high variability in the treatment effect, depending of surgical 
technique.
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Objectives: During the progressive course of type 2 diabetes mellitus (T2DM) a 
sizeable proportion of patients require insulin therapy to maintain long-term glyce-
mic control. The objective of this study was to realize a snapshot of characteristics 
and glycemic control of patients with T2DM treated by insulin in five European 
countries. MethOds: T2DM patients, over 40 years old, treated by insulin (basal 
only therapy [BOT], premix, prandial or a basal-prandial free combination) ± non-
insulin antidiabetic drugs for at least 18 months, were identified in primary care 
electronic medical record databases of France, Italy, UK; Germany and Spain (IMS 
Health Longitudinal Patient Databases) during years 2013-2014. Patients’ charac-
teristics, medical history, treatment regimen, HbA1c values were retrieved and 
analyzed Results: Median age was 71.4 years in Italy (n= 7339), 70 in Germany 
(n= 3079), 67 in UK (n= 16,941), 68.2 in France (n= 3046) and 70.3 in Spain (n= 1710). 
About half of patients had a BMI ≥ 30 and hypertension was present in 69% (UK) to 
88% (Germany). A majority was treated with BOT in France (51%) and Spain (60%), 
basal-prandial in Italy (48%) and in Germany (33%), and premix insulin in UK (41%). 
BOT was the second most commonly prescribed regimen in Germany and Italy. 
Metformin was the most frequently prescribed concomitant oral antidiabetic drug. 
Mean HbA1c was 7.8% in Italy, 7.7% in Germany, 8.4% in UK, 7.9% in France and 8% 
in Spain. Overall, more than three quarter of patients (between 74% in Italy and 
83% in UK) had a HbA1c ≥ 7%, whilst 33% (Germany) to 55.5% (UK) of them had 
a HbA1c ≥ 8%. cOnclusiOns: While regimens and patients characteristics may 
vary among countries, these results show that, despite having been treated with 
insulin for at least 18 months, a sizeable proportion of patients exhibit a suboptimal 
glycemic control.
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Objectives: With the introduction and delisting of some glucose-lowering medi-
cations, pharmacological treatments in T2D have changed in the recent years and 
details of the current drug use patterns are not known. This descriptive study aims 
to describe characteristics of patients with type 2 diabetes and patterns of use of 
antihyperglycemic agents in France in 2013. MethOds: A random sample of ≈ 
600,000 patients registered in the French national health insurances reimburse-
ment database was used. Patients with diabetes were identified through their use of 
glucose-lowering medication and coding of hospital stays and long-standing condi-
tion insurance coverage in the database. Drug utilization pattern of antihyperglyce-
mic agents were estimated considering prescriptions in Q4 2013 and compared to 
data from Q4 2007. Results: Overall 28,708 patients with T2D (estimated database 
prevalence 4.5%, 8.8% in people aged 40 and over) were identified in 2013. Mean age 
was 67.5 (SD 12.9), 54.1% were male. In Q4, 41.2% of T2D pharmacologically treated 
patients received a monotherapy, 25.6% a dual therapy, 13.7% a multi-therapy and 
19.5% an insulin therapy with or without other hypoglycemic agents. Compared to 
2007 data, a slight but significant increasing trend toward combination therapies 
and insulin was observed. The use of metformin increased over time especially in 
monotherapy (66% among monotherapy in 2013 versus 50% in 2007). All thiazolidin-
ediones and some sulfonylureas treatments were replaced by DPP-4 inhibitors and 
to a much lesser extent with GLP-1 analogues. cOnclusiOns: Antihyperglycemic 
prescription patterns in France have changed in recent years in parallel with the 
introduction of different classes of medications to the marketplace but probably 
also in an attempt to improve glycemic control of patients. Knowledge of real life 
pattern of drug utilization remains an important dimension to better understand 
therapeutic needs in T2D management.
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Objectives: Diabetes in the elderly is a major challenge both in terms of clinical 
management and of public health. Evidence about prescribing patterns in the elderly 
diabetic population is limited. The aim of the present study was to describe trends in 
antidiabetic drug (AD) utilization patterns in the elderly in Southern Italy with a focus 
on drugs for cardiovascular prevention and pharmaceutical costs. MethOds: The 
data used for this retrospective cross-sectional study was obtained from pharmacy 
records of Caserta Local Health Authority. Subject > 65 years who received at least 
one dispensing of antidiabetic between January2010-December2014 were selected. 
be more efficacious than other GLP-1 analogues in reducing HbA1c (mean change 
-1.1%/-1.2% for liraglutide 1.2mg/1.8mg; -0.6%/-0.9% exenatide 5mcg/10mcg BID; 
-0.6% lixisenatide 20mcg). Liraglutide was superior or comparable to other GLP-1 
analogues in terms of weight, PPG, SBP, and FPG. cOnclusiOns: Liraglutide offers 
efficacious treatment in terms of HbA1c, FPG, PPG, SBP compare to other GLP-1 
analogues and seems to offer a weight control advantage among patients on mul-
tiple OADs. The likelihood of hypoglycemic events does not appear to differ among 
GLP-1s. Our analysis was limited by the relatively small number of studies available 
and we were not able to adjust for some observed differences in patient charac-
teristics, which may have affected the evaluation. As such, the findings should be 
interpreted with some caution.
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Objectives: To evaluate relative efficacy and safety of SGLT2i compared to DPP4i 
in patients with type 2 diabetes mellitus (T2DM) in the absence of head-to-head 
evidence. MethOds: A systematic search of the literature was conducted in 
MEDLINE, EMBASE, LILACS, the Cochrane Central Register of Controlled Trials, and 
Clinicaltrials.gov to June 2015. Selected studies were randomized controlled trials 
(RCTs) that compare DPP4i plus insulin (DPP4i/INS) or SGLT2i plus insulin (SGLT2i/
INS) with placebo plus insulin (PCB/INS), as a common comparator, in patients 
with T2DM. The primary outcome was the change in HbA1c from baseline to the 
end of the intervention period. The secondary outcomes included the change in 
fasting plasma glucose, the change in body weight, and the event of hypoglyce-
mia. Covariate-adjusted indirect comparison using meta-regression analyses was 
performed. Results: We included 15 eligible RCTS comprising 6,980 patients, of 
which 9 were DPP4i studies and 5 were SGLT2i studies. Covariate-adjusted analy-
ses showed that SGLT2i/INS achieved greater reduction in HbA1c (WMD -0.24%, 
95% CI -0.43 to -0.05%) and fasting plasma glucose (WMD -18.0mg/dL, 95% CI -28.5 
to -7.6 mg/dL) with greater weight reduction (WMD -2.38 kg, 95% CI -3.18 to -1.58 
kg) than DPP4i/INS without increasing the risk of hypoglycemia (RR 1.19, 95% CI 
0.78 to 1.82). cOnclusiOns: The addition of SGLT2i on top of pre-existing insulin 
therapy exhibits a better glycemic control and greater weight reduction than DPP4i 
in patients with inadequately controlled T2DM.
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Objectives: Sodium-glucose transport protein 2 (SGLT-2) inhibitors demonstrate 
favorable efficacy profiles that include glycemic control and reductions in body 
weight but are associated with adverse events including ketoacidosis, urinary 
tract infections, candida vulvovaginitis, and hypoglycemia. This comparative 
safety and efficacy analysis is designed to compare relevant clinical endpoints 
in the prescribing information labels of available SGLT-2 inhibitors and identify 
the most prevalent and clinically significant outcomes which are crucial in the 
management of patients with type 2 diabetes (T2D). MethOds: A multivariate 
analysis was undertaken using clinical endpoints from product information labels 
(n= 3; canaglifozin, dapagliflozin, empagliflozin) of available SGLT-2 inhibitors. 
Compounds with 24- to 26-week, placebo-controlled endpoint data were analyzed. 
Efficacy endpoints included change from baseline in hemoglobin A1c (%) and 
body weight (kg). The safety endpoints included percentage of patients reporting 
adverse events, including urinary tract infections, female genital mycotic infec-
tions, and incidence of hypoglycemic events (%). Results: No compound outper-
formed competitors in all predefined outcome measures after 24- to 26- weeks 
of treatment. Canagliflozin 300 mg + metformin reported the greatest reduction 
in body weight (-4.07 kg) and the greatest reduction in HbA1c (-1.06%). However, 
canagliflozin 300 mg + metformin (4.6%) reported the greatest incidence of hypo-
glycemia events and the greatest incidence of urinary tract infections (11.4%) 
after 26 weeks. cOnclusiOns: Despite the robust efficacy profiles presented in 
this analysis, physicians should consider the potential adverse events associated 
with each SGLT-2 inhibitor before deciding on a treatment regimen. Diabetes treat-
ment regimens are often highly individualized, and healthcare providers must 
weigh the benefits of any treatment with its attendant risks. Of special concern 
among SGLT-2 inhibitors is the recent US FDA warning of increased risk for diabetic 
ketoacidosis associated with these compounds.
PDB12
“efficacy anD safety Bariatric surgery vs. clinical treatMent in 
control of levels glyceMic anD reMission DiaBetes Mellitus tyPe ii 
in Patients oBese”
Zanghelini F1, Buehler AM2, Pereira Td2
1Universidade Federal de Pernambuco, Recife, Brazil, 2Hospital Alemão Oswaldo Cruz, São Paulo, 
Brazil
Objectives: Evaluate the results on the efficacy and safety of bariatric surgery vs. 
medical treatment in remission of type 2 diabetes mellitus (T2DM) and control of 
blood glucose levels in patients with Body Mass Index ≥ 30. MethOds: Following 
the methodological guidelines for the development of PTC Ministry of Health, was 
first drafted the guiding question of the study through the PICO, then a search was 
conducted in the main databases (PubMed, Embase, Cochrane, Lilacs and CRD). Each 
study recovered in the databases was selected and evaluated by two independent 
researchers, their inconsistencies resolved by consensus, when there was no con-
